RE: TMAC back on15 Mar 2025 13:18
I’m also referring back to BV’s helpful posts on AVA3996 and bortezomib as well as this thread.
CC: “One of the next medicines we’re looking to make is a targeted therapy.”
CC: “We hope to see one of those coming soon to the clinic”
You what! Just take a look at the expression on CC’s face when she makes this last statement. She’s struggling to stop herself grinning like a Cheshire Cat.
CC: “It’s not just chemotherapy, I know the first two have been sort of traditional chemotherapy’s”. CC is referring to AVA6000 and AVA6103 which she discussed previously in the interview. Clearly states “Exetecan is our next precision medicine”
CC talks of targeted therapy and explains pathway inhibitors “carry very high toxicities” so therapeutic index a problem which pre|CISION can solve.
Next, and quite separately, CC then goes on to describe Avacta’s third box of IP ie affimers and biological drug conjugates leading to idea of taking on the ADC’s. Here CC clearly referring to AffDC with AV7100 in mind.
With the emphasis on a type of targeted therapy, I lean more towards the definition of “pathway inhibitors” that work by blocking specific signaling pathways that drive cancer cell growth and spread. Blocking rather than the process of breaking down.
TOPO1 inhibitors induce DNA damage to cause cell death and proteasome inhibitors break down proteins hence both AV6103 and AVA3996 are seen more as a chemo treatment by CC. In fact, Avacta have always put AVA3996 firmly in the chemo camp when communicating news on progress with this drug.
On the basis of the toxicity comments, Tyrosine kinase inhibitors (TKIs) might be most likely. They work by blocking tyrosine kinase enzymes. TKI enzymes help manage how cells work, including cell signaling and growth and how often cells divide. However TKIs widely used for STS so very unlikely. Truth is there are a myriad of possibilities for the payload.
The thing is we are told “coming soon to the clinic”. Didn’t say in early development, nearing IND stage etc. Does that mean Avacta have already devoted time,money and resources (they didn’t have!) to this new medicine? Back in 21 we were told Avacta were looking at a number of other opportunities for expanding pre|CISION such as AKT inhibitors, PARP inhibitors, TKIs, and these were being evaluated through early stage preclinical work. Is this a resurrection of something promising from the past?
The medicine clearly exists but isn’t mentioned in the context of Avacta’s current, much trumpeted pipeline. Why on earth not?
Also, why would CC use a casual interview to clearly define that one of the next Gen 1 or 2 pre|CISION medicines is going to be a “targeted therapy” and it’s coming soon especially since Avacta’s pipeline has been the centrepiece of its strategy since it was revealed in Oct 24. Presumably this new targeted medicine is hot on the heels of AV6103. Would it be ahead
Sign In
Follow the stocks
